Improving accountability in vaccine decision-making

ABSTRACT Introduction: Healthcare decisions, in particular those affecting entire populations, should be evidence-based and taken by decision-makers sharing broad alignment with affected stakeholders. However, criteria, priorities and procedures for decision-making are sometimes non-transparent, frequently vary considerably across equivalent decision-bodies, do not always consider the broader benefits of new health-measures, and therefore do not necessarily adequately represent the relevant stakeholder-spectrum. Areas covered: To address these issues in the context of the evaluation of new vaccines, we have proposed a first baseline set of core evaluation criteria, primarily selected by members of the vaccine research community, and suggested their implementation in vaccine evaluation procedures. In this communication, we review the consequences and utility of stakeholder-centered core considerations to increase transparency in and accountability of decision-making procedures, in general, and of the benefits gained by their inclusion in Multi-Criteria-Decision-Analysis tools, exemplified by SMART Vaccines, specifically. Expert commentary: To increase effectiveness and comparability of health decision outcomes, decision procedures should be properly standardized across equivalent (national) decision bodies. To this end, including stakeholder-centered criteria in decision procedures would significantly increase their transparency and accountability, support international capacity building to improve health, and reduce societal costs and inequity resulting from suboptimal health decision-making.

[1]  N. Dickert,et al.  Justifying Clinical Nudges. , 2017, The Hastings Center report.

[2]  R. Rappuoli,et al.  Core values for vaccine evaluation. , 2017, Vaccine.

[3]  S. Ozawa,et al.  Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States. , 2016, Health affairs.

[4]  E. Nicod Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries , 2016, The European Journal of Health Economics.

[5]  Jane J. Kim,et al.  Cost-effective management of women with minor cervical lesions: Revisiting the application of HPV DNA testing. , 2016, Gynecologic oncology.

[6]  L. Callahan,et al.  Item response theory analysis of Centers for Disease Control and Prevention Health-Related Quality of Life (CDC HRQOL) items in adults with arthritis , 2016, Health and Quality of Life Outcomes.

[7]  Zoltán Kaló,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  Maarten J. IJzerman,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  A. Sherwood,et al.  Does Conditional Marketing Authorisation Influence Market Access in France, England, and Germany? , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Mirjam Knol,et al.  Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community , 2015, PharmacoEconomics.

[11]  N. MacDonald Vaccine hesitancy: Definition, scope and determinants. , 2015, Vaccine.

[12]  H. Larson,et al.  Measuring vaccine hesitancy: The development of a survey tool. , 2015, Vaccine.

[13]  D. Bloom Valuing vaccines: deficiencies and remedies. , 2015, Vaccine.

[14]  Glennis A. Logsdon,et al.  Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality , 2015, Science.

[15]  D. Levy-bruhl,et al.  Characteristics and practices of National Immunisation Technical Advisory Groups in Europe and potential for collaboration, April 2014. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[16]  Karl Claxton,et al.  Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold. , 2015, Health technology assessment.

[17]  M. Drummond,et al.  Comparison of NITAG policies and working processes in selected developed countries. , 2015, Vaccine.

[18]  R. Sanson-Fisher,et al.  Health research priority setting in selected high income countries: a narrative review of methods used and recommendations for future practice , 2014, Cost Effectiveness and Resource Allocation.

[19]  S. Black Potential long term vaccine benefits poorly translate in cost effectiveness modelling , 2014, BMJ : British Medical Journal.

[20]  W. Edmunds,et al.  Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study , 2014, BMJ : British Medical Journal.

[21]  Marc Fleurbaey,et al.  Guidance on priority setting in health care (GPS-Health): the inclusion of equity criteria not captured by cost-effectiveness analysis , 2014, Cost Effectiveness and Resource Allocation.

[22]  Till Bärnighausen,et al.  Valuing vaccination , 2014, Proceedings of the National Academy of Sciences.

[23]  R. Baltussen,et al.  Legitimate Healthcare Limit Setting in a Real-World Setting: Integrating Accountability for Reasonableness and Multi-Criteria Decision Analysis , 2014 .

[24]  C. Reh Is informal politics undemocratic? Trilogues, early agreements and the selection model of representation , 2014 .

[25]  J. Raftery,et al.  NICE’s Cost-Effectiveness Range: Should it be Lowered? , 2014, PharmacoEconomics.

[26]  Bruce Y. Lee,et al.  Reassessing the value of vaccines. , 2014, The Lancet. Global health.

[27]  Anne Peters The Transparency of Global Governance , 2014 .

[28]  Mike Paulden,et al.  NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[29]  Jenny de Fine Licht,et al.  When Does Transparency Generate Legitimacy? Experimenting on a Context‐Bound Relationship , 2014 .

[30]  S. Black The role of health economic analyses in vaccine decision making. , 2013, Vaccine.

[31]  O. Wichmann,et al.  National Advisory Groups and their role in immunization policy-making processes in European countries. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[32]  S. Omer,et al.  Epidemiology of vaccine hesitancy in the United States , 2013, Human vaccines & immunotherapeutics.

[33]  J. Mekalanos Vaccine Economics: What Price Human Life? , 2013, Science Translational Medicine.

[34]  Philip R. Johnson,et al.  Accelerating Next-Generation Vaccine Development for Global Disease Prevention , 2013, Science.

[35]  Matthew Hickman,et al.  Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impact , 2013, Vaccine.

[36]  D. Fryback,et al.  Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint , 2013 .

[37]  J. Frenk,et al.  Governance challenges in global health. , 2013, The New England journal of medicine.

[38]  M. Jit,et al.  Key issues for estimating the impact and cost-effectiveness of seasonal influenza vaccination strategies , 2013, Human vaccines & immunotherapeutics.

[39]  A. Dowsett The price of prevention: what now for immunisation against meningococcus B? , 2013 .

[40]  Rob Baltussen,et al.  Mapping of multiple criteria for priority setting of health interventions: an aid for decision makers , 2012, BMC Health Services Research.

[41]  K. Marsh,et al.  Estimating cost-effectiveness in public health: a summary of modelling and valuation methods , 2012, Health Economics Review.

[42]  Jane J. Mansbridge Clarifying the Concept of Representation , 2011, American Political Science Review.

[43]  D. Canning,et al.  The effect of vaccination on children's physical and cognitive development in the Philippines , 2011 .

[44]  P. Rota,et al.  Health care-associated measles outbreak in the United States after an importation: challenges and economic impact. , 2011, The Journal of infectious diseases.

[45]  N. Devlin,et al.  Incorporating Multiple Criteria in HTA: Methods and Processes , 2011 .

[46]  S. J. Whitehead,et al.  Health outcomes in economic evaluation: the QALY and utilities. , 2010, British medical bulletin.

[47]  M. Jit,et al.  A brief history of economic evaluation for human papillomavirus vaccination policy. , 2010, Sexual health.

[48]  David Barnett,et al.  Pharmacoeconomics: NICE's approach to decision-making. , 2010, British journal of clinical pharmacology.

[49]  B. Gessner,et al.  Informing decision makers: experience and process of 15 National Immunization Technical Advisory Groups. , 2010, Vaccine.

[50]  J. Bryson,et al.  A systematic review of national immunization policy making processes. , 2010, Vaccine.

[51]  S. Grosse Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold , 2008, Expert review of pharmacoeconomics & outcomes research.

[52]  Sue J Goldie,et al.  Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches. , 2008, PharmacoEconomics.

[53]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[54]  G. Carrin,et al.  Clarifying Efficiency-Equity Tradeoffs Through Explicit Criteria, With a Focus on Developing Countries , 2005, Health Care Analysis.

[55]  Jane J. Mansbridge The fallacy of tightening the reins , 2005 .

[56]  M. Little Setting limits fairly: can we learn to share medical resources? , 2004 .

[57]  Douglas K. Martin,et al.  Fairness, accountability for reasonableness, and the views of priority setting decision-makers. , 2002, Health policy.

[58]  Norman Daniels,et al.  Setting Limits Fairly: Can We Learn to Share Medical Resources? , 2002 .

[59]  H. Glick,et al.  Economic Evaluation of Vaccination Programmes , 2002, PharmacoEconomics.

[60]  Robert O. Keohane,et al.  Global Governance and Democratic Accountability , 2002 .

[61]  H. Glick,et al.  Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. , 2002, PharmacoEconomics.

[62]  Bruce E. Barrett,et al.  The efficacy of SMARTER — Simple Multi-Attribute Rating Technique Extended to Ranking , 1996 .

[63]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[64]  E. P. Seskin,et al.  The economic value of life: linking theory to practice. , 1982, American journal of public health.

[65]  G. Psacharopoulos Rates of Return to Investment in Education around the World , 1972, Comparative Education Review.